Studies also suggested that scopolamine-induced cognitive impairments may be linked to its suppression of Nrf2 activity and related treatments activating Nrf2 signaling pathways (Venkatesan et al., 2016; Li et al., 2024). The gene discussed is NFE2L2; the disease is Cognitive impairment.